Paolo Bicchieri is the associate editor for the Northern California and Pacific Northwest region writing about restaurant and bar trends, coffee and cafes, and pop-ups. On a warm afternoon on 16th ...
We recently published a list of Small Stocks, But Explosive: These 10 Firms Crushed The Market Last Week. In this article, we are going to take a look at where Spero Therapeutics, Inc. (NASDAQ:SPRO) ...
GSK plc (NYSE:GSK) and Spero Therapeutics Inc (NASDAQ:SPRO) on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) ...
"Usate la papamobile per curare i bimbi di Gaza": l'ultima richiesta di Papa Francesco prima di morire L'ultimo desiderio di Papa Francesco prima di morire: usare la papambile per curare i bimbi di ...
Cambiano i tempi di attuazione ed alcune misure previste nella riforma fiscale (Legge delega 111/2023). Con un apposito ddl approvato in Consiglio dei Ministri, da un lato si prorogano i termini per l ...
Le modifiche apportate dal “Correttivo-ter” al Codice della crisi di impresa e dell’insolvenza introducono la possibilità di accedere alla transazione fiscale, che nell’ambito del concordato ...
Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical ...
This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...
Spero Therapeutics, Inc. (SPRO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
Fintel reports that on December 20, 2024, Evercore ISI Group downgraded their outlook for Spero Therapeutics (NasdaqGS:SPRO) ...
A downtrend has been apparent in Spero Therapeutics, Inc. (SPRO) lately with too much selling pressure. The stock has declined 9.3% over the past four weeks. However, given the fact that it is now in ...
Spero Therapeutics (NASDAQ:SPRO) stock tumbled 20% post-market after the company announced it was cutting its workforce by 39% in the wake of a failed Phase 2 study for its drug SPR720. In a statement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback